Zhang Z.H. et al. (2015) found that MCM2 could promote cell proliferation by regulating HMCMGA1 phosphorylation, which was previously reported to be related to the malignant status and poor prognosis of NSCLC. MCM2 has also been reported as a potential therapeutic target of lovastatin for NSCLC (Zhang X. et al., 2015). MCM4 is one of the six MCM proteins composing the prereplicative complex that binds to replication origins in the G1 phase of the cell cycle, and it was essential for the initiation of DNA replication (Kikuchi et al., 2011). Here, MCM4 is linked to non-small cell lung carcinoma.